Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness and safety

Conclusion Despite low rate of response, flu and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research